Singular Health Group (ASX:SHG) has spent the past year turning a piece of Australian imaging software into a US commercial story, and its June 2026 quarterly gave investors the clearest scorecard yet. In the report lodged recently in late July, the company confirmed a US$500,000 licence payment from its Florida partner, 750 primary care provider licences running its 3DICOM MD platform, and a cash balance of $10.1 million. For a micro-cap medtech, the mix of recurring US revenue, a fresh FDA clearance and a two-year funding buffer is the sort of combination that separates a genuine commercial trajectory from a perpetual promise. The question now is whether the deployment converts into renewals and materially larger contracts.

What just happened

The headline event of the June quarter was a contracted US$500,000 payment from Provider Network Solutions (PNS), the Florida-based managed services organisation that has become Singular Health’s anchor US customer. The payment flowed under a binding enterprise agreement first struck in mid-2025 and followed the deployment of an additional 500 licences, lifting the total across the PNS network to 750.

That commercial progress sits on top of a regulatory milestone earlier in the year. Recently in January 2026, Singular Health Group (ASX:SHG) announced US Food and Drug Administration 510(k) clearance for 3DICOM MD Cloud, a Class II Software as a Medical Device. The FDA completed its review in 40 days, well inside the roughly 90-day norm. The cloud clearance builds on the desktop version of 3DICOM MD, which was cleared back in 2022.

Why it matters

The clearance is more than a compliance tick. The desktop product required hardware and IT installation at each site, a real friction point for clinics. The cloud version strips that out, which matters when the growth plan depends on signing up primary care practices at scale rather than one radiology department at a time. In plain terms, Singular Health can now sell a browser-based tool that lets doctors open and manipulate CT, MRI, PET, X-ray and ultrasound scans in 3D without a specialist workstation.

That is the crux of the Investment case: moving advanced image viewing out of the hospital and into the GP’s office, where duplicate scans and lost images are a chronic cost.

The numbers that matter

The verified figures paint a company early in commercialisation. Cash stood at $10.1 million at 30 June 2026, which management frames as roughly two years of runway. That balance was underpinned by an $8 million Placement completed alongside the PNS agreement, in which PNS and Marin & Sons each took $150,000.

On the Revenue side, the PNS framework is priced at US$800 per 3DICOM MD licence, with the original agreement valued at around $2 million. The 750 licences now deployed represent the tangible base, and management has flagged that those licences expire at the end of the third quarter of calendar 2026, making renewal the next real test. A separate Florida pilot with Life Radiology, using 3DICOM Gateway and Patient products, had enrolled more than 230 patients over about 15 weeks and shifted imaging delivery from CD-ROM to digital.

The bigger industry picture

Singular Health is chasing a specific inefficiency. Every year, US patients undergo repeat scans because prior images cannot be found, shared or opened across incompatible systems. The company cites a US total addressable market of roughly US$16.5 billion tied to reducing unnecessary duplicate imaging.

The broader tailwinds are real. US healthcare is under pressure to cut waste and push more diagnostic work into primary care, and interoperability has become a policy priority — Singular Health has taken part in a US Office of the National Coordinator consultation on the issue. Digital health tools that plug images into the point of care, rather than trapping them in hospital PACS archives, fit that direction of travel. Singular Health also maintains ISO 27001, HIPAA and SOC 2 Type II certifications, with HITRUST in progress — table stakes for selling into US payers.

The bull case

The optimistic reading is that Singular Health has moved from proof-of-concept to a repeatable US motion. It has a cleared cloud product, a paying anchor customer serving several million members across Florida, and adjacent footholds: a rollout of 3DICOM EDU to Miami-Dade County Public Schools, the third-largest US school district, with a first student cohort due in September 2026, plus an MoU with Florida International University. If the PNS licences renew and expand to affiliates and other payers, the per-licence model could compound quickly without heavy incremental cost, given the software is now cloud-delivered.

The risks

The risks are equally plain. Revenue remains concentrated in a single partner, and the 750 licences are up for renewal at the end of Q3 CY2026 — a milestone, not a guarantee. Deployment figures are encouraging, but licence counts are not the same as durable recurring revenue, and payment timing has been lumpy. The company is still loss-making and reliant on the placement proceeds to fund the rollout, so any slippage in US conversion tightens the runway. Engagement with Puerto Rico health plan Triple-S and Florida project funding are described as ongoing rather than contracted. As with any micro-cap, illiquidity and capital-raising dilution are live considerations, and technology and clinical benefits remain company claims until independently borne out at scale.

What happens next

Several catalysts sit inside the next two quarters. First, the PNS licence renewal decision expected around the end of Q3 CY2026 will show whether the anchor customer commits for the longer term. Second, outcomes on Florida project funding and the Triple-S engagement are flagged for the same window. Third, the Miami-Dade student cohort launch in September 2026 will test the education channel. Fourth, any expansion of PNS use to affiliates or new payers would signal the model travels. Fifth, progress on HITRUST certification and the Medical File Transfer Protocol Patent filings could strengthen the moat.

Conclusion

Singular Health has assembled the ingredients that a US-focused digital health story needs: a cleared cloud product, a paying customer, recurring per-licence pricing and enough cash to see the thesis tested. The June quarter showed the deployment is real, not theoretical. But the company is still early, still concentrated and still loss-making, and the decisive evidence lies just ahead — whether 750 licences renew, whether new payers sign, and whether pilots in Florida and Puerto Rico convert into contracts. For now, the platform has cleared the regulatory hurdle; the commercial one is where the story is decided.